# Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance), Division 3.4.2.1.2.3

Extent: E+W+S+N.I.

The evidence referred to above could be:
(a) clinical history and data from appropriate lung function tests related to exposure to the substance, confirmed by other supportive evidence which may include:
(i) in vivo immunological test (e.g. skin prick test);
(ii) in vitro immunological test (e.g. serological analysis);
(iii) studies that indicate other specific hypersensitivity reactions where immunological mechanisms of action have not been proven, e.g. repeated low-level irritation, pharmacologically mediated effects;
(iv) a chemical structure related to substances known to cause respiratory hypersensitivity;
(b) data from one or more positive bronchial challenge tests with the substance conducted according to accepted guidelines for the determination of a specific hypersensitivity reaction.

---
Source: https://www.legislation.gov.uk/eur/2008/1272/annex/I/division/3/division/3.4/division/3.4.2/division/3.4.2.1/division/3.4.2.1.2/division/3.4.2.1.2.3 (the official version)
Page: https://openlegislation.uk/eu-regulation-2008-1272/annex-I/division-3/division-3.4/division-3.4.2/division-3.4.2.1/division-3.4.2.1.2/division-3.4.2.1.2.3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

